Gross Margin

Struggling Inno Holdings rolls the dice with a massive reverse stock split to avoid delisting, but grim financials and a brutal market reaction raise alarms.

A new study reveals Gen X faces a shocking $400K retirement shortfall, caught between fading pensions and an imperfect 401(k) system. Are they prepared?

SCALE AI's record funding fuels 44 new projects, aiming to accelerate homegrown AI and secure Canada's digital future amid fierce global competition.

Beijing touts its Sanjiangyuan project as a win for ecology and herders. But beyond the state narrative lies a complex story of coercion and cultural risk.

A new FDA clearance for its AI software enhances Hyperfine's portable MRI, positioning it to disrupt the lucrative stroke diagnostics market. Here's why.

As Natuzzi prepares its Q3 results, the luxury furniture maker's costly bet on Italian craftsmanship faces a critical test amid a tough economy.

The crypto giant reports massive growth, but a pivot to AI, operational fires, and rising debt reveal a risky strategy to reshape global computing power.

As New Jersey's cannabis market booms, Grown Rogue's one-year success reveals a potent strategy for blending craft quality with low-cost execution.

Canada’s condo market is in transition. With prices down and inventory up, a unique opportunity emerges for buyers before a projected 2027 recovery.

The infrastructure giant's new €800M share repurchase isn't just for shareholder value; it's a strategic move to fund future growth and acquisitions.

As winter storms loom, a silent threat enters our homes. Learn the critical, life-saving steps to protect your family from carbon monoxide and fire.

A deep dive into Perma-Pipe's record-breaking quarter, revealing a strategy of regional dominance and savvy diversification into high-growth tech sectors.

Fresh off its IPO, iOThree is pushing AI and certified digital tools. Can its innovation engine and Asian expansion overcome market headwinds?

As Uxin prepares to report Q3 results, all eyes are on its ambitious superstore strategy and whether it can drive profitability in a complex market.

Genmab's $8 billion acquisition of Merus isn't just a deal; it's a bold strategy to own its destiny and dominate the future of oncology therapeutics.

Lument Finance Trust's latest dividend boasts an attractive yield, but recent adjustments raise questions about the health of commercial real estate.

BrightView Holdings declared its eighth straight cash dividend, a move signaling financial discipline even as it navigates revenue challenges and stock volatility.

A routine filing reveals a major strategic play. See how BridgeBio Oncology uses special equity grants to attract top minds in the fierce race for a cancer cure.

Argan's repeated dividend hikes and record backlog reflect deep confidence, positioning it to capitalize on surging demand for critical energy infrastructure.

As TD SYNNEX prepares its full-year report, the results will be a crucial test of its AI strategy and a key indicator for the entire IT ecosystem.